Stock 8YY BIOLIDICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Biolidics Limited Stock

Equities

8YY

SGXE89830751

Advanced Medical Equipment & Technology

Delayed Singapore S.E.
Other stock markets
 04:27:11 2024-04-17 am EDT 		5-day change 1st Jan Change
0.012 SGD 0.00% Intraday chart for Biolidics Limited 0.00% -14.29%
Apr. 12 Biolidics Limited Announces the Redesignation of Zhu Hua from Non-Executive Non-Independent Director to Executive Director CI
Apr. 12 Singapore Shares Fall at Market Close; Biolidics Up 9% MT

Financials

Sales 2021 2.33M 1.71M Sales 2022 2.54M 1.86M Capitalization 11.84M 8.7M
Net income 2021 -5M -3.68M Net income 2022 -9M -6.62M EV / Sales 2021 21.8 x
Net Debt 2021 289K 213K Net cash position 2022 2.02M 1.48M EV / Sales 2022 3.87 x
P/E ratio 2021
-8.41 x
P/E ratio 2022
-0.72 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 54.05%
More Fundamentals * Assessed data

Chart Biolidics Limited

Dynamic Chart

Latest news about Biolidics Limited

Biolidics Limited Announces the Redesignation of Zhu Hua from Non-Executive Non-Independent Director to Executive Director CI
Singapore Shares Fall at Market Close; Biolidics Up 9% MT
Biolidics’ Loss Narrows in 2023 as Revenue Slumps 47%; Shares Surge 9% MT
Biolidics to Issue Shares Worth Over SG$360,000 to New Director MT
Biolidics Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Biolidics Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Biolidics Limited Announces the Change of its Registered Office Address CI
Biolidics Issues Over 87 Million Shares to Sponsor, Investor MT
Biolidics Obtains Bourse's Nod to List Over 87 Million Shares MT
Biolidics to Issue SG$50,000 of Shares to Sponsor as Partial Payment of Professional Fee MT
Biolidics to Raise Over SG$1 Million from Share Placement MT
Biolidics Ropes in Evolve Capital Advisory as Sponsor MT
Biolidics Limited Appoints Zhu Hua as A Non-Executive Non-Independent Director CI
Clearbridge Health Receives Full Amount of Outstanding Debt from Biolidics MT
Biolidics Issues 98.5 Million Shares Under Subscription Agreement; Shares Jump 8% MT
More news

Analyst Recommendations on Biolidics Limited

Biolidics to Issue Shares Worth Over SG$360,000 to New Director MT
More recommendations

Press releases Biolidics Limited

Biolidics to Commence Commercial Production of its ClearEpi SARS-COV-2 Neutralising Antibody Rapid Test Kit AQ
General Announcement::UPDATE ON DEVELOPMENT OF THE CLEAREPI SARS-COV-2 NEUTRALISING ANTIBODY RAPID TEST KIT PU
Response to SGX Queries:: PU
General Announcement::Appointment and Re-designation of directors; and Changes to the composition of the Board PU
Aytu BioScience : Announces Exclusive Distribution Agreement for COVID-19 IgG or IgM Rapid Test with Singapore-Based Biolidics Limited AQ
More press releases

Quotes and Performance

3 months-7.69%
6 months-20.00%
Current year-14.29%
More quotes

Highs and lows

1 week
0.01
Extreme 0.01
0.01
1 month
0.01
Extreme 0.01
0.01
Current year
0.01
Extreme 0.01
0.01
1 year
0.01
Extreme 0.01
0.02
3 years
0.01
Extreme 0.01
0.35
5 years
0.01
Extreme 0.01
0.89
10 years
0.01
Extreme 0.01
0.89
More quotes

Managers and Directors - Biolidics Limited

Managers TitleAgeSince
Tang Yih Song CEO
 Chief Executive Officer 59 21-08-31
Hafiza Alwi Nor SEC
 Corporate Secretary - -
Yeung Sau Siu AUD
 Comptroller/Controller/Auditor 50 22-05-31
Members of the board TitleAgeSince
Tang Yih Song CEO
 Chief Executive Officer 59 21-08-31
Li-Ling Ch'ng BRD
 Director/Board Member 53 23-03-30
Yoke Pheng Liew BRD
 Director/Board Member 68 Nov. 26
More insiders

Quotes

Date Price Change Volume
24-04-17 0.012 0.00% 651,500
24-04-16 0.012 0.00% 2,985,500
24-04-12 0.012 +9.09% 5,106,300
24-04-11 0.011 -8.33% 206,900
24-04-09 0.012 +9.09% 2,025,000

Delayed Quote Singapore S.E., April 17, 2024 at 04:27 am EDT

More quotes

Company Profile

Biolidics Limited is a Singapore-based precision medicine medical technology company. The Company's principal activities are technology development, technology transfer, marketing, selling and distribution of biomedical technology, life and medicine science related products and services; provision of laboratory services; and investment holding. It has three segments: cancer diagnostics, infectious diseases and laboratory services. Cancer diagnostics segment develops and commercializes the ClearCell FX1 System, a fully automated CE-IVD medical device, which separate and enrich cancer cells from blood, allows users of the system to perform liquid biopsies. Infectious diseases segment develops, markets and/or distributes certified test kits with various diagnostic partners. Laboratory services segment offers a range of tests. The laboratory has a regulatory approval from Singapore’s Ministry of Health for molecular microbiology testing and PCR testing services for COVID-19 in Singapore.
Sector
Advanced Medical Equipment & Technology
Calendar
2024-04-25 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
BIOLIDICS LIMITED Stock Biolidics Limited
-14.29% 6.55M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+3.10% 212B
DANAHER CORPORATION Stock Danaher Corporation
+3.48% 178B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+10.91% 134B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+17.56% 100B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-0.99% 62.45B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+14.41% 54.2B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-6.21% 44.74B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-3.22% 40.09B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+10.18% 39.19B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. 8YY Stock